SECRET is an open-label, randomized, controlled, phase II study that will assess the safety of rivaroxaban, a non-vitamin K antagonist oral anticoagulant (NOAC), compared with standard-of-care (unfractionated or low-molecular weight heparin with transition to warfarin [INR 2.0-3.0], or continued low molecular-weight heparin) for cerebral venous thrombosis. Recruitment will occur at 15 high-volume stroke research centres across Canada over 3 years. Three hundred and forty-eight adult patients within 14 days of diagnosis of symptomatic cerebral venous thrombosis will be randomized to receive rivaroxaban 20 mg daily versus standard-of-care (regimen at the discretion of the local investigator in keeping with AHA/ASA guidelines). Patients will be followed for 1 year. The feasibility of recruitment will also be tested.